Advertisement
Research Article| Volume 34, ISSUE 3, P471-476, May 2020

Treatment of Patients with Vocal Fold Atrophy and Comorbid Essential Voice Tremor: Long-Term Injection Augmentation Outcomes After Successful Diagnostic Vocal Fold Injection Augmentation

  • Maxine Van Doren
    Affiliations
    Division of Otolaryngology, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts

    Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts
    Search for articles by this author
  • Elizabeth Faudoa
    Affiliations
    Division of Otolaryngology, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts

    Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts
    Search for articles by this author
  • Thomas L. Carroll
    Correspondence
    Address correspondence and reprint requests to Thomas L. Carroll, Division of Otolaryngology, Department of Surgery, Brigham and Women's Hospital, 45 Francis St., Boston, MA 02115.
    Affiliations
    Division of Otolaryngology, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts
    Search for articles by this author
Published:November 29, 2018DOI:https://doi.org/10.1016/j.jvoice.2018.11.004

      Summary

      Objective

      Vocal fold injection augmentation (VFIA) is employed diagnostically for patients with subtle glottic insufficiency. Its use in patients with both vocal fold atrophy and benign essential voice tremor (EVT) has been reported but not after durable augmentation. This study intends to evaluate the success of durable VFIA using either autologous fat or calcium hydroxylapatite in patients with both vocal fold atrophy and comorbid EVT.

      Methods/Design

      Retrospective review. Subjects included demonstrated subtle glottic insufficiency from true vocal fold atrophy and comorbid EVT with no other vocal fold pathology. Voice Handicap Index (VHI-10), aerodynamic data including subglottic pressure and airflow, and the tremor scoring scale were evaluated before diagnostic VFIA with carboxymethylcellulose and after durable VFIA with calcium hydroxylapatite or autologous fat.

      Results

      Seven patients met inclusion criteria. Six subjects went on to durable VFIA. Three of six demonstrated meaningful improvement in the VHI-10 score. Subglottic pressure improved significantly in those subjects with meaningful VHI-10 improvement compared to those that did not. The tremor did not resolve completely in any subject, but patient satisfaction and function was improved in four of the six.

      Conclusions

      VFIA for EVT in the setting of true vocal fold atrophy appears to offer benefit and may be an alternative treatment pathway for EVT patients. More than half of the subjects who underwent durable VFIA after successful diagnostic VFIA reported improvement in their communication despite inconsistent objective outcomes. Subglottic pressure improved significantly in half of the subjects who also reported a substantive improvement in their VHI-10.

      Level of Evidence

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Voice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barkmeier-Kraemer J
        Updates on vocal tremor and its management.
        Perspect Voice Voice Dis. 2012; 22: 97-103
        • Massy EW
        • Paulson GW
        Essential voice tremor: clinical characteristics and response to therapy.
        Southern Med J. 1985; 78: 316-317
        • Lester RA
        • Barkmeier-Kraemer J
        • Story BH
        physiologic and acoustic patterns of essential vocal tremor.
        J Voice. 2013; 27: 422-432
        • Lederle A
        • Barkmeier-Kraemer J
        • Finnegan E
        Perception of vocal tremor during sustained phonation compared with sentence context.
        J Voice. 2012; 26 (668.e1-668.e9)
        • Sulica L.
        • Louis E.D.
        Clinical characteristics of essential voice tremor: a study of 34 cases.
        The Laryngoscope. 2010; 120: 516-528
        • Orbelo DM
        • Duffy JR
        • Hughes Borst BJ
        • et al.
        Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
        J Voice. 2014; 28: 123-127
        • Estes C
        • Sadoughi B
        • Coleman R
        • et al.
        A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.
        The Laryngoscope. 2018; 128: 437-446
        • Nida A
        • Alston J
        • Schweinfurth J
        Primidone therapy for essential vocal tremor.
        JAMA Otolaryngol Head Neck Surg. 2016 Feb 1; 142: 117-121
        • Justicz N
        • Hapner ER
        • Josephs JS
        • et al.
        Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor.
        The Laryngoscope. 2016; 126: 113-117
        • Barkmeier-Kraemer J
        • Lato A
        • Wiley K
        Development of a speech treatment program for a client with essential vocal tremor.
        Semin Speech Lang. 2011; 32: 043-057
        • Pitman MJ.
        Chapter 89: Spasmodic Dysphonia. Sclafani Total Otolaryngology-Head and Neck Surgery.
        Thieme Medical Publishers, New York2015
        • Carroll TL
        • Rosen CA
        Trial Vocal Fold Injection.
        J Voice. 2010; 24: 494-498
        • Carroll TL
        • Faudoa E
        • Van Doren M
        Evaluation of a shorter follow-up time to capture benefit of a trial vocal fold augmentation.
        J Voice. 2018 Jan; ([cited 2018 May 31]; Available from:)
        • Young VN
        • Jeong K
        • Rothenberger SD
        • et al.
        Minimal clinically important difference of voice handicap index-10 in vocal fold paralysis.
        The Laryngoscope. 2018; 128: 1419-1424
        • Carroll TL
        • Wu Y-HE
        • McRay M
        • et al.
        Frame by frame analysis of glottic insufficiency using laryngovideostroboscopy.
        J Voice. 2012; 26: 220-225
        • Bové M
        • Daamen N
        • Rosen C
        • et al.
        Development and validation of the vocal tremor scoring system.
        The Laryngoscope. 2006; 116: 1662-1667
        • Carroll TL
        • Dezube A
        • Bauman LA
        • et al.
        Using trial vocal fold injection to select vocal fold scar patients who may benefit from more durable augmentation.
        Ann Otol Rhinol Laryngol. 2018; 127: 105-112